How to Appraise the Evidence Behind an Aesthetic Procedure

To appraise the evidence behind a cosmetic or aesthetic procedure, ask three questions before you look at any photograph. What regulatory bar did the device or product actually clear? Were the results measured against a comparator using a validated scale, or just shown as a picture? And for how long were both the benefit and the harms tracked? A striking before-and-after image answers none of these. This is an evidence-literacy piece, not a recommendation of any procedure, device, or brand.

Start with the regulatory category, because it sets the evidence floor

The first thing to establish is what a product legally is, because that determines how much evidence had to exist before it reached the market. The categories are not interchangeable, and the marketing rarely makes the distinction clear.

Injectable soft-tissue fillers are regulated by the FDA as medical devices, and the ones cleared for facial and hand use went through Premarket Approval, the agency's most demanding device pathway. The FDA states that its approval of these fillers is based on data collected from controlled clinical studies that evaluated safe and effective use when the product was injected into specified areas of facial tissue and the hands. That is a meaningful evidence bar. It is also narrow, because approval attaches to a specific material, a specific injection site, and a specific indication, not to the general idea of "filler."

Topical products sit in a different world. Under the Federal Food, Drug, and Cosmetic Act, whether something is a cosmetic or a drug turns on its intended use, which the FDA infers from the claims made about it. A product intended only to beautify or alter appearance is a cosmetic, and the law does not require FDA approval before a cosmetic goes on the market. The moment a product claims to affect the structure or function of the body, including the skin, or to treat or prevent disease, it meets the legal definition of a drug and must satisfy drug requirements. The FDA is explicit that "cosmeceutical" has no meaning under the law and does not lower that bar. So a serum promising to "rebuild collagen" is making a structure-function claim that, taken at face value, describes a drug, even though it is usually sold with the evidence expectations of a cosmetic. That gap between the claim and the evidence category is the first thing to notice.

Interrogate the study design behind the claim

Once you know the category, look at how the underlying studies were built. Aesthetic outcomes are unusually vulnerable to bias because so much of the endpoint is subjective and because expectation shapes perception.

Ask who was compared to whom. A single-arm series in which everyone receives the treatment and reports feeling better tells you little; a randomized comparison against a control, ideally with blinded assessors rating standardized photographs, tells you much more. Ask how the outcome was measured. Validated instruments, such as established wrinkle-severity or aesthetic-improvement scales scored by an evaluator who does not know which treatment a subject received, are far more trustworthy than an untrained "satisfaction" tally. Ask who paid for the study and who designed it, and whether the results were published in full or only presented as a favorable summary. None of these questions require a statistics degree. They require reading past the headline number to the sentence that describes the comparator.

Weigh durability against the reporting window

Durability is where aesthetic marketing and aesthetic evidence most often diverge. A result photographed at the peak effect says nothing about the trajectory afterward.

The FDA's own material shows how much durability depends on the substance. Most approved fillers are absorbable and temporary. By the agency's account, hyaluronic-acid products last approximately six to twelve months, calcium hydroxylapatite lasts approximately eighteen months, and poly-L-lactic acid, given as a series of injections over several months, may last up to about two years. The FDA has approved only one filler made from a material that remains in the body and is not absorbed, a product using polymethylmethacrylate beads. That single fact reframes the appraisal question. A longer-lasting or permanent material is not automatically better, because any problem is also longer-lasting or permanent. When you read a durability claim, check that the follow-up period in the study is at least as long as the claimed benefit. A twelve-month promise supported by three months of data is an extrapolation, not a finding.

Read the harms reporting as carefully as the benefits

The weakest section of most aesthetic evidence is harms, and it is the section that matters most to a reader deciding whether a low-probability but serious risk is acceptable.

The FDA notes that most filler side effects, such as swelling and bruising, occur shortly after injection and many resolve in a few days to weeks. But it also warns that the most concerning risk, unintentional injection into a blood vessel, can block blood supply to tissues and lead to complications that include necrosis, vision abnormalities including blindness, and stroke; the chances are low, but the resulting harm can be permanent. The agency also states that some side effects may appear weeks, months, or years after injection. That timeline is the appraisal lesson, because a study that follows patients for twelve weeks cannot characterize a harm that surfaces in year two. When you evaluate a harms table, look at how adverse events were collected (actively solicited or passively reported), how long surveillance ran, and whether rare serious events were counted at all or were simply absent because the sample was too small to detect them. Absence of reported harm is not evidence of safety; it is often just evidence of a short, small study. The FDA's separate recommendation against using fillers for body contouring and enhancement is a reminder that using an approved product outside its studied indication moves you outside the evidence entirely.

Putting these together gives a simple discipline. Identify the regulatory category and the evidence floor it implies, check that outcomes were measured against a comparator on a validated scale, confirm the follow-up window covers the claimed durability, and read the harms reporting for both severity and surveillance length. This is educational information about how to read evidence, not medical advice, and it does not endorse or discourage any specific procedure.